La chaîne d'options affiche les données clés des options sur actions de Midland States Bancorp à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Midland States Bancorp..

Midland States Bancorp (NASDAQ:MSBI) Stock, Chaîne d'Options

MIDLAND STATES BANCORP INC

Midland States Bancorp

Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment which generates the majority of the revenue, provides a wide range of financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage and other consumer loan products; commercial equipment financing etc. The Wealth Management segment consists of trust and fiduciary services, brokerage and retirement planning services. The Other segment includes the operating results of the parent company.

Midland States Bancorp, Inc. - Common Stock

Midland States Bancorp Inc

Midland States Bancorp, Inc. - Depositary Shares Each Representing a 1/40th Interest in a Share of 7.750% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A

GE Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) is passing along higher prices to customers after U.S. trade tariffs created a $500 million cost burden, meaning airlines, and eventually passengers, will soon <a href="https://www.benzinga.com/topic/tariffs">feel the heat.</a>
Speaking from New Delhi at the International Air Transport Association's annual meeting, chief executive officer Larry Culp told Bloomberg that the world's largest aircraft engine maker is no longer able to shield customers from the financial impact of trade restrictions introduced under President Donald Trump's policies.
"We will be taking cost actions and passing along some of that residual," Culp said.
<h3 class="wp-block-heading">Is GE Already Seeing The Tariff Impact?</h3>
"Very much so," Culp said when asked whether the tariffs are affecting business now. The company has seen rising expenses and is adjusting its pricing strategy to preserve margins.
"We're managing the best we can, mitigating where we can through those supply-chain improvements but also through the cost and price actions," he said.
<h3 class="wp-block-heading">Tariff-Free Trade Helped Build US Aerospace</h3>
For decades, the global aerospace industry benefited from the 1979 Civil Aviation Agreement, which allowed for duty-free trade among key nations. 
Culp said that the framework helped U.S. companies like GE and Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) build a $75 billion annual trade surplus in aviation. But that advantage is eroding under new trade barriers.
"We've been advocating for a return to where we were on the heels of that 1979 civil aviation agreement," he said.
The U.S. has already signed a trade deal with the U.K., and more negotiations are underway. 
"I think June will be an important month," Culp added, as more agreements could shape the future cost landscape for aerospace exports.
<h3 class="wp-block-heading">Production Pressure Grows As Airbus And Boeing Ramp Up</h3>
GE is working to keep pace with increasing production from both Airbus SE and Boeing Co., who are planning record monthly output levels. 
"Be it with Airbus, be it with Boeing, they are effectively sold out through the rest of this decade," Culp said.
GE holds a $170 billion backlog and expects to build more engines in the second half of 2025 and in 2026 than in the first half of this year. 
Culp said parts received from key suppliers in April and May rose double-digits compared to the first quarter, a sign that the company's supply chain efforts are starting to pay off.
GE is also a major supplier to the U.S. Department of Defense, powering two-thirds of the U.S. combat aircraft and helicopters. Culp said the company remains focused on long-term military contracts and advanced engine development as defense spending increases.
When asked about growing concern over technology exports to China, Culp said GE has followed strict government procedures for years and is prepared for tighter controls if they come. 
"We welcome the scrutiny," he said.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45715850/trump-administration-silently-employs-palantir-to-gather-personal-data-of-each-american-raising-privacy-data-misuse-concerns-report">Trump Administration Silently Employs Palantir To Gather Personal Data Of Each American, Raising Privacy, Data Misuse Concerns: Report</a></li>
</ul>
Photo: Shutterstock

Get Ready To Pay The Price Of Tariffs: GE Is Already Passing Costs To Customers

Wedbush analyst David Nierengarten downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Outperform to Neutral and raises the price target from $128 to $129.

News

Downgrades

Price Target

Analyst Ratings

BPMC

Wedbush Downgrades Blueprint Medicines to Neutral, Raises Price Target to $129

Contracts

Diana Shipping Inc. Secures Time Charter Contract For Newcastlemax Vessel m/v Newport News At $25,000 Per Day With Bohai Ocean Shipping Through June To October 2026, Projecting ~$10.95M Gross Revenue For Minimum Charter Period

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">82.76</td>
<td align="right">1.23</td>
<td align="right">1.50</td>
<td>81.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.85</td>
<td align="right">0.51</td>
<td align="right">0.59</td>
<td>8.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">132.71</td>
<td align="right">0.07</td>
<td align="right">0.05</td>
<td>4.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">100.77</td>
<td align="right">-0.63</td>
<td align="right">-0.63</td>
<td>4.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.71</td>
<td align="right">-0.25</td>
<td align="right">-0.50</td>
<td>151.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.57</td>
<td align="right">-0.16</td>
<td align="right">-0.39</td>
<td>2.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">230.02</td>
<td align="right">-0.89</td>
<td align="right">-0.39</td>
<td>13.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">142.30</td>
<td align="right">-0.52</td>
<td align="right">-0.37</td>
<td>2.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">213.04</td>
<td align="right">-0.76</td>
<td align="right">-0.36</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.69</td>
<td align="right">-0.23</td>
<td align="right">-0.29</td>
<td>10.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.70</td>
<td align="right">-0.13</td>
<td align="right">-0.16</td>
<td>5.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 2, 2025

CERo Therapeutics Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of&nbsp; engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying&nbsp; mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by &nbsp;the European Patent Office, all of which significantly expand the Company's intellectual property portfolio.

CERO

CERo Therapeutics Secures Key U.S. And European Patents For Next-Gen T Cell Therapies

Mizuho analyst Maheep Mandloi maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Outperform and lowers the price target from $16 to $13.

Mizuho Maintains Outperform on Sunrun, Lowers Price Target to $13

<a href="https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai" title="https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai">https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai</a>

BABA

'How Alibaba Helped China Take the Lead From the U.S. in Open-Source AI' - The Information

CETX

Cemtrex's Vicon Receives $0.8M Contracts From U.K. Correctional Facilities

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled "<a href="https://www.globenewswire.com/Tracker?data=B-RN4N7zHYvKUcdnjlk4jtgfVTPS2vdvJO8iwTfiBBQKgcGy73ar6qKxYKUSQGCyhZlU8iU25vJPDpq-Py27VtL8RMaAeAYYH8VDAoQflHL4J3VgRcOg3S3xvZuFl_zErpFmLBusrqy1dx8nVX7TT26x5aRVrFfN3s48dpx1OHoJvAKl6ec0x76h0rkWNwg1ACmHbWI3Rei8CuA4sof5mWssyBPzpfRSLwkvjI2YsOzPjG7KCdv2nEzTG64q_qRbp6dw9BQA2KOU7R0B2et_Mv32ywfx5dyEHK3CzMVpbRxeeO15huBs6bT7oLzU3piEkCqWeOINLkOq956W9SisJUwSrWtTWRwmTyETP7w185JpH0Nkl4zV1l76j62-WrmuRp1bEuHANGZtJPKblL_GURjd2rdCPGhqW4HxQ-I0bS-Hj6jzqt1akX3PXcckl42Km8-RghXycIO7tACZHaEbWGubp2h2wxvkDS7cr0LFcIXcIQOXKQUgYnre5osm0liUtN7CYOkL3q3lAOlJ5gV6ktumZ_7ZRVBP3ghWQ02OJ83xfX2ybud5XrLg7Chpe6bauNL76O0UmAqm4AetGCX98xMcmVIDc1QI10GCwCq80KJz3TPSm0bwNVimcvG0HcQGXddY1Vd6CzichWAPGs3WkEKwJY5pKFFQmg_1CMjQVaXAWc_VbUV7LEzasTQD44b-12jfW37MIlcnQm8VeXyXTo-vTsQxWj0jIWmFGQopKPwHB5FS4Y75kLeAhnBxhD9Du8AAlpfsbzes2iNbPqHuo15jHsd2wrS48QajBft3aDXKmdKyPYTsRfoZcMAjcfpYDZX5h2TsHaOJ7AfKcywPtahZaFYTTbKq3fmHvoVUZuvTBxLE-dQVXtOoupqQtQMpQ3-GAtRErvTO0pNQUKAt-1s-JcHUIfjMww815oeTB_9tpiOQ4SZK-VSfG4wx72Id6J5Mp0z0VwkYtcaL0TqVKETDao4ezhfrV4vqpZ4wSAVDVIL5hBAkNDLZsbbq10iV6EZRSltD0gWTQW-mHeDCXshBp8oce7BkAGtoPpYyesoDAoOwofiVeBFIrcwx_rz3wB3UWN4-C09cD4WtObDHYkKzecAXO9ZWnJN2aCCjRTzq3GVTUrY51fUyYpgXKxILjgsdOJxgaTVFAucXh435z-d3mxAzNvNUkxKeBWhpVy3wa_YF0Jgb5LyOb7mmPRv-fRnPuOZbpZTxvaSTnNucMSHKV1m0WCwJJb_8Y4QYMBClpw_vK25nbysSVICSUTtv73_cNxBzUpA6SUsnGV-VyYs55xZF3SuqQgO4849OgHJm1utK1f_q6RuPRx6_-l8vzWPDhkmArnkee6iLlzbRJPzfFEj7Nev9vGZbBRmv6iwwkRihobf85fwS1DpwzUa_5S97iZHM7d2377H9nCe3OCBAYhgm-qtut3cB4FGw7r4gzHDEbOYPiWSh2zEj92h1Y8jxKY73PopD1aqcvUxEEkNvXuXG2JxC3E_IDY6yJCs61DAgDcU0EcXdgQlsApTP4s9nIQ74zhE4yCJxxmV7xURXVjC8V75mvN60Gf_uXW4qCLhgqNbJNq5LI3fi20Y7jzBKScqNscKx7WqENT6qU8xzo3EAVpuiHbYUQf_aqjC5TytUmazd7338gB_iOy1qVXxXc5EJLXbFjQ2zO443ypPIsFpQGLy2gsMnGzVyUiJ5UIcP2F04BMjaU2uwn9wKyX_BI50sdQNvOwW5rtLRKQw-CCCxYDZCSCRMZGikoGiVs9ahpLrRVYV6MrIe_It9Iy8yWQnASweTB8LKKljy0kdJY08jEUyp768owoVyBj_3JYabbE21Qb6ANI_Cf7ZKZPqNpf1rjCvsuErctjj3UYXVyFvYFBOZHEDq7r4dcmgmc8Jp36KPwAjQw9Dj1tI2HYxWQbvxAtipMoPwLnAMKRob7JwQfdnrwYjLLVbtG_j_CRQ4AgfHj2YQUgmoQDh1EYKeq0ceogsacnxmsPUM9X0VSpFzuRkW2EjA7FEXxxvfkEdGpGAoxlRYejYmU8ctJs__2r_sTlx1pMzaWpa-xYNEhjS5wy6mFe22lgCBKx6UdecX_FwaE3ohf9U9RgXk7eaI2jhmPlQiXNUeNTfM_Tq8hp5y1KlF64sPwg0N6m-8oYIRIjKx3vTr5ulOhlefIcKI6C525fTw8etoHJQs5wd7I9apqcw1RkUqHns_j85Jxvx2Nl3-CQoqLmmfiDqV22UiwjSDNF5rckmM4eayMElC4dmUoTTMQ3k56Q-hIb2Qa9vXQoRpSowCSs0SMLn5GM3_RJUDl_aixjxD2YQjavah63li0pVrRzrY1rDrONeVL8eVoQMcQplvUhTpWF-SwVBwJ9BoeAwSCxV0YdJa6x-SzXKQHGXwKMMdU5b4KmX1rAvFlog5MaEmKUQOrZkA5uQt30UenpGnd5kdbJYj3w0M7xHesA-k6_1pWottxahsRm9NwT1JC8kBKt_t2Zorkd2SdycTxQIdNDHu2tTddktCiS0vCtlFrA8LvVi6s3Pd1_kOKdp6Xkf9LkxoFroY9WHxa0sVbmcDkKtfVOzjlIq78skeN0tx_mIJyYrsr6g1oOFRjc7tHgj42nmK25w5qem2orvWwv83boISDW1CmRRh6-A06f_5g4sGIn1Zz3tWKbuI9O1l3FRre4HoQCn_miaFoNKbmLCh-_1bmfrH30ClrIyby7xe6uW65cfcON1XA-7mnvtPAwSuSySbKsa0h0DW6PXkF3V0AaJUYflTQ9YWERjMAH9qMVODCUDOW3CCJB0xRgzmbqKvTuuHp00su6JUkTKCst39-HAvJpuKsAleAkvlwZZ7-Fs0s1IMH4Ufu433dKoXQWCJhOQx2-06aa5ogdCt-f8rYA8JU_NZ3Km5TKJTEIACMzkhew4OR_3IgskJd-v7LsRpCK5X9CftLsRmrluOfS3XObAIgI5NIYd4kvuWw-CrVeWApCbUD4rpoGpqgyO1Z-XvdgLAXFjjLwsKktuokSUUSEM0TwqrvdKGmxdtlq4yl8OP78pERag=">Fatty acid binding proteins and their involvement in anxiety and mood disorders</a>," that underscores the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders.
The peer-reviewed article was co-authored by Doctor Steven Laviolette, Professor in the Schulich School of Medicine along with other researchers from the University of Western Ontario, Canada, details extensive preclinical evidence supporting FABP5, FABP3, and FABP7 as key regulators of lipid trafficking, neuroinflammatory signaling, and endocannabinoid tone — mechanisms critically involved in the pathophysiology of anxiety and depression.

Biotech

General

ARTL

Artelo Biosciences Welcomes Publication Of Peer-Reviewed Review Highlighting Therapeutic Potential Of Fatty Acid Binding Protein Inhibitors In Treating Anxiety And Mood Disorders, Underscoring Key Roles Of FABP5, FABP3, And FABP7 In Neuroinflammation And Endocannabinoid Regulation

Mizuho analyst Maheep Mandloi maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Neutral and raises the price target from $15 to $18.

SEDG

Mizuho Maintains Neutral on SolarEdge Technologies, Raises Price Target to $18

<a href="https://www.globenewswire.com/Tracker?data=t6BzLIYkM2Titjo2engsbYdYzVAKdATUpngXwVnOZLIFJeWOfs8JrzmA569pg5PP_wzcfVu2vxAkFgwTviT40sMP1XwBJn9-iup44hY2Ll8=">Myriad Genetics, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual disease (MRD) clinical data from the MONSTAR-SCREEN 3 study, a collaboration with the National Cancer Center Hospital East (NCCHE) in Japan, demonstrating successful pan-cancer implementation of Myriad's ultra-sensitive Precise&#x2122; MRD Test to detect and monitor ctDNA in patients.
The interim results – first shared at the <a href="https://www.globenewswire.com/Tracker?data=BdItqSDA6Al6o-I38SIC8HVerhVbF4nmX3ccqI_QUByE92yXbvem_fZDt7OQiI8cB2NKQK4abOO6M6jL-D0tMte8h9L5gZyDFjQTEqQDUNNJPBB4ksABOeMgezfAqA3z09nF2QurM9LI5SGkqo5aWA==">2025 ASCO Annual Meeting</a> by Tadayoshi Hashimoto, MD, PhD of the NCCHE – achieved 100% baseline detection of ctDNA across tumor types, including those traditionally challenging to assess because of low levels of ctDNA in blood. Key findings include:
<ul>
<li>Personalized whole-genome sequencing (WGS) panels utilizing up to 1,000 somatic variants were successfully created via Precise MRD for 97.3% of patients tested.</li>
<li>Precise MRD detected tumor fractions as low as 0.0001% (1 part per million) and showed a clinically meaningful lead time in detecting recurrence compared to imaging.</li>
<li>Clearance of ctDNA during neoadjuvant chemotherapy, as shown by Precise MRD, predicted pathological complete response. &nbsp;</li>
</ul>
"Previous studies have shown that ctDNA-based MRD detection significantly correlates with recurrence risk and predicts benefit of adjuvant chemotherapy in certain cancers," said Takayuki Yoshino, MD, PhD of the NCCHE and principal investigator for the MONSTAR-SCREEN-3 study. "However, first-generation MRD assays appear to have limited sensitivity in low ctDNA-shedding tumors. For our pan-cancer study, we selected Precise MRD because of its enhanced sensitivity across diverse tumor types."
"Our results showed that among samples that were ctDNA-positive at the one-month post-surgery timepoint, 60% had ctDNA levels in the ultra-sensitive range that may not have been reported as positive by first generation MRD tests," said Dr. Hashimoto. "In addition, these patients had significantly worse disease-free survival compared to those that were ctDNA-negative, demonstrating the importance of ultra-sensitive ctDNA detection."
"The initial results from the study highlight the tremendous potential for utilizing Precise MRD across cancer types to enhance personalized treatment and therapeutic strategies for patients," said Dale Muzzey, PhD, chief scientific officer, Myriad Genetics. "Precise MRD is informed by WGS, enabling the tracking of thousands of tumor-specific sites, far more than what is possible with first-generation MRD tests. Tracking so many variants yields exceptional sensitivity even in cancers with low shedding tumors such as breast and renal. A key benefit of our ultrasensitive assay is confidence in ctDNA results, as shown by the finding that the ctDNA status after neoadjuvant treatment was strongly associated with pathological response."

MYGN

Myriad Genetics Announces MONSTAR-SCREEN 3 Data, Advancing Pan-Cancer MRD Testing

<ul>
<li>Authorized expanded access for ANKTIVA to treat lymphopenia, a life-threatening immune deficiency induced by chemotherapy, radiotherapy, and immunotherapy with depletion of natural killer (NK) and CD4+ CD8+ T cells (lymphocytes)</li>
<li>Expanded Access includes all patients with solid tumors who have failed first-line treatment on chemotherapy, radiotherapy or immunotherapy and exhibit low Absolute Lymphocyte Counts (ALC &lt;1,000/μL)
<ul>
<li>Presentation at ASCO Annual Meeting 2025 of lymphopenia treatment in patients with 3rd to 6th line metastatic pancreatic cancer significantly prolongs overall survival</li>
</ul>
</li>
</ul>

IBRX

ImmunityBio Receives FDA Expanded Access Authorization For Treatment Of Lymphopenia With ANKTIVA In Patients With Solid Tumors

Board Initiates CEO Search Process
Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed
Company Reaffirms Full Year 2025 Outlook
LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors.
The Nature's Sunshine Board has initiated a comprehensive search process, with the assistance of a nationally recognized executive search firm, to identify the Company's next President and Chief Executive Officer.

Guidance

Management

NATR

Nature's Sunshine Products Announces CEO Terrence Moorehead To Step Down Upon Successor Appointment, Board Launches Executive Search Process While Reaffirming Full Year 2025 Outlook

Stock Split

CLRO

ClearOne Authorizes 1-fFr-15 Reverse Stock Split

- Expert Insights on Clinical Relevance and Scientific Rationale - The replay of the event is available on the Investor Relations section of the Actuate website
CHICAGO and FORT WORTH, Texas, June 02, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced key takeaways from its <a href="https://www.globenewswire.com/Tracker?data=ny_7s0D-DqkX-BPpPbP_wQtFovQZxuvRSw4gk6tVSoZGjR14bMEO2op3qnVein761Xie2vWUKkbXa0LDrdeZEVTJl4Aw6C1DeRqFFuuqeg1BPOdvquOX2UW3UpV2FF0pjjU7STsQjumtaJ5ZutZM1w==">Key Opinion Leader (KOL) event</a> held on May 31, 2025 discussing the positive topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
The study met its primary endpoint, demonstrating a clinically meaningful increase in median overall survival (mOS) of 10.1 months compared to 7.2 months (p = 0.01), with a 37% reduction in the risk of death (HR = 0.63). The elraglusib/GnP arm also doubled the 12-month survival rate in 44.1% of patients compared to GnP alone (22.3%), with a favorable safety profile.
The KOL event followed the presentation of topline trial data during an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting. The event featured a fireside discussion with leading mPDAC clinicians, all with direct participation in the elraglusib clinical trial program: Colin Weekes, MD, PhD, Massachusetts General Hospital; Devalingam Mahalingam, MD, Northwestern University Feinberg School of Medicine; Rachna Shroff, MD, MS, FASCO, University of Arizona Cancer Center; Tanios Bekaii-Saab, MD, FACP, Mayo Clinic College of Medicine and Science.
The panelists highlighted the implications of the Phase 2 Actuate 1801 Part 3B results in the broader context of the unmet need in mPDAC, the unique immune-modulating mechanism of elraglusib, and its potential to reshape the treatment landscape, as follows.

ACTU

Actuate Therapeutics Highlights Insights On Phase 2 Trial Results Showing Clinically Meaningful Survival Benefit And Favorable Safety Of Elraglusib Combined With Gemcitabine/Nab-Paclitaxel In Untreated Metastatic Pancreatic Cancer At KOL Event

Mizuho analyst Maheep Mandloi maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Outperform and raises the price target from $6 to $7.

SHLS

Mizuho Maintains Outperform on Shoals Technologies Gr, Raises Price Target to $7

The new task order is the first to be fulfilled under the $450 million Production-Other Transaction Agreement recently awarded to C3 AI.

C3 AI Wins $13M Order To Expand Predictive Maintenance Program Across U.S. Air Force Fleet

Palladyne AI included in annual reconstitution of the Russell U.S. Indexes capturing 4,000 largest U.S. stocks for 2025
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.palladyneai.com%2F&amp;esheet=54262364&amp;newsitemid=20250602973600&amp;lan=en-US&amp;anchor=Palladyne+AI+Corp&amp;index=1&amp;md5=e4e79a7c27f7d29dbdcb80a7a8a87be9">Palladyne AI Corp</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) ("Palladyne AI"), a developer of artificial intelligence software for robotic platforms in the defense and commercial sectors, today announced that it has been added as a member of the broad-market Russell 3000&#xAE; Index, effective after the U.S. market opens on June 30, 2025, as part of the 2025 Russell indexes reconstitution.
The annual reconstitution of the Russell U.S. indexes captures the 4,000 largest US stocks as of April 30, 2025, ranking them by total market capitalization. Membership in the Russell 3000Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000&#xAE; Index or small-cap Russell 2000&#xAE; Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

PDYN

Palladyne AI Corp. To Join Russell 3000 And Russell 2000 Index, Effective After The U.S. Market Opens On June 30, 2025

TD SYNNEX Appoints Kenneth Lamneck As Chair Of Nominating And Corporate Governance Committee

Mizuho analyst Anthony Crowdell maintains Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Outperform and raises the price target from $60 to $67.

Comments

Midland States Bancorp

Midland States Bancorp (MSBI) Options

Midland States Bancorp (NASDAQ:MSBI) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL